Nominations for the 2014 award are now closed.
The Award and Lecture
The AACR and Eli Lilly and Company established this award in 1961 to honor Dr. G.H.A. Clowes, who was a founding member of the AACR and a research director of Eli Lilly. The Clowes Award recognizes an individual with outstanding recent accomplishments in basic cancer research.
The recipient of the 54th Annual AACR G.H.A. Clowes Memorial Award will receive a $10,000 honorarium, give a 50-minute lecture during the AACR Annual Meeting 2014 in San Diego, Calif., USA (April 5-9, 2014), and will be given support for the winner and a guest to attend the Annual Meeting. The winner will also speak at the Eli Lilly and Company headquarters in Indianapolis, Ind., at the invitation of the company later in 2014.
- Candidacy is open to all cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry or government.
- The award will be presented to an individual investigator.
- Institutions or organizations are not eligible for the award.
Nomination Procedure and Instructions
Nominations are closed.
Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science. Candidates may not nominate themselves.
Nomination materials to be submitted are:
1) Nomination Letter Must:
- be addressed to the Selection Committee; be written in English; and not exceed 1,000 words;
- specify the AACR Award for which the candidate is being nominated;
- contain a concise description of the candidate's outstanding recent accomplishments in basic cancer research, with the publications supporting these accomplishments directly referenced within the letter;
- contain a concise description of the impact of these accomplishments on the field; and
- be signed by the nominator(s).
2) Candidate's CV. The candidate's curriculum vitae in English, including a complete list of the candidate's publications.
3) Summary Statement. A statement, no more than 50 words, summarizing the candidate's research accomplishments for which he or she is being nominated.
Full nomination instructions and program guidelines are available through the link below and on the proposalCENTRAL website.
Program Guidelines and Nomination Instructions. Download the Adobe Acrobat Reader here.
Candidates will be considered by a committee of international cancer leaders appointed by the president of the AACR. After careful deliberations by the Award Committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision. Selection of the award winner will be made on the basis of the candidate’s recent accomplishments in basic cancer research. No regard will be given to age, race, gender, nationality, geographic location or religious or political views.
Generously supported by Eli Lilly and Company.
Linda Stokes, Program Associate
American Association for Cancer Research
17th Floor, 615 Chestnut Street
Philadelphia, PA 19106-4404
53rd Annual Award Recipient
Michael R. Stratton, Ph.D.
Director, The Wellcome Trust Sanger Institute
Wellcome Trust Sanger Institute
Dr. Stratton delivered his award lecture titled The Causes of Mutations in Human Cancer
, at the AACR Annual Meeting 2013 in Washington, D.C. The award ceremony and lecture was held on Monday, April 8, 2013. Visit the AACR Annual Meeting 2013
page for more information on the Annual Meeting.
Dr. Michael R. Stratton is honored for his outstanding contributions to cancer research through groundbreaking contributions in the area of cancer genomics and genetics.
Highlights of Dr. Stratton’s accomplishments include discovery of the breast cancer susceptibility gene BRCA2 and somatic mutations of the BRAF gene in malignant melanoma and other cancers. He proposed the bold concept of a Cancer Genome Project that subsequently led to founding of the International Cancer Genome Consortium, which aims to sequence the genomes of thousands of human cancers in the next five to ten years.
Dr. Stratton led the group that mapped and identified BRCA2 at the Institute of Cancer Research in London, U.K. The breakthrough discovery of BRCA2 by Stratton directly transformed the lives of thousands of women in families with a history of breast cancer through predictive testing and prevention. Subsequent studies by his research team led to discovery of the first low-penetrance breast cancer predisposition gene, CHEK2, followed by identification of additional low-penetrance breast cancer predisposition genes, ATM, BRIP1 and PALB2 and the mapping and positional cloning of susceptibility genes underlying other types of cancer.
Following the success of human genome sequencing, he shifted his interests from genetic susceptibility of cancer to understanding somatic mutations, and moved to the UK genome center at the Wellcome Trust Sanger Institute to implement his vision employing genome-wide sequencing to identify somatic mutations in human cancers. This led to the discovery of somatic mutations in BRAF, a serine threonine kinase gene mutated in 60 percent of malignant melanomas. This remarkable discovery has led to the development of BRAF inhibitors, which provide hope for patients with melanoma. In addition, Dr. Stratton and his colleagues discovered intragenic activating mutations of ERBB2 in non-small cell lung cancer, driver mutations of a series of genes implicated in chromatin regulation including UTX, JARID1C, SETD2, ARID1B, NCOR1, SMARCD1, PBRM1 and other genes including MAP3K1, CASP8 and TBX3.
Dr. Stratton conducted large-scale resequencing of human cancer genomes, initially sampling a large fragment of genomic DNA constituting the coding exons of the complete protein kinase family in 210 cancers. The resultant identification of more than 1,000 mutations demonstrated that patterns of somatic point mutations in cancer genomes are highly variable and established the concepts of “driver” and “passenger” mutations. In recent years, Stratton and his colleagues have used powerful second-generation sequencing, and the outcomes of these studies have provided great insights into the complexity of patterns of rearrangement and point mutation in solid tumor genomes leading to new ideas concerning mutagenesis in human cancer.
Another major accomplishment of Dr. Stratton, and a major contribution to society, is the creation of the COSMIC (Catalog of Somatic Mutations in Cancer) database, the only comprehensive database with annotations of about 200,000 somatic mutations in cancer, gathered from scientific literature.
Dr. Stratton obtained his medical degree from Oxford University and Guys Hospital, trained as an histopathologist at the Hammersmith and Maudsley Hospitals and obtained a doctorate in molecular biology at the Institute of Cancer Research, London. After joining the Sanger Institute in 2000, he was promoted to deputy director in 2007 and was appointed director in 2010. He was awarded the Lila Gruber Cancer Research Award in 2010 and the Louis-Jeantet Prize for Medicine for his work on cancer genetics and genomics in 2013. Stratton is an elected Fellow of the Royal Society and the European Molecular Biology Organization.